Restaurant Brands International Inc. Common Shares vs TG Therapeutics Inc — how do they compare? Restaurant Brands International Inc. Common Shares trades at $71.08 (market cap $24.56B), while TG Therapeutics Inc trades at $54.84 (market cap $8.16B). The key difference: Restaurant Brands International Inc. Common Shares is far larger — about 3× TG Therapeutics Inc's market cap, and Restaurant Brands International Inc. Common Shares pays a 3.68% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Restaurant Brands International Inc. Common Shares for 0 Days and TG Therapeutics Inc for 16 Days on average.
| QSR | TGTX | |
|---|---|---|
Market Cap | $24.56B | $8.16B |
Volume | 3,480,368 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $81.67 | $59.06 |
52-Week Low | $65.69 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $39.17B | $8.37B |
Dividend Yield | 3.68% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Restaurant Brands International owns and franchises quick-service restaurant brands, including Burger King, Tim Hortons, Popeyes, and Firehouse Subs.
Read more on QSR →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →